Disopyramide Sustained-Release Capsules and Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets
Determining the interaction of Disopyramide Sustained-Release Capsules and Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Ritonavir may significantly increase the blood levels of disopyramide. This can increase side effects such as dry mouth, abdominal pain, constipation, blurred vision, difficulty urinating, low blood sugar, low blood pressure, and potentially life-threatening irregular heart rhythm and conduction abnormalities. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or special monitoring by your doctor to safely use both medications. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with disopyramide. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR CLOSELY: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of disopyramide, which is primarily metabolized by the isoenzyme. High plasma levels of disopyramide may increase the risk of QT interval prolongation, which has been associated with ventricular arrhythmias including torsade de pointes and sudden death. Other adverse effects such as hypoglycemic coma and ventricular fibrillation have also been reported.
MANAGEMENT: Caution is advised when disopyramide must be used concomitantly with potent CYP450 3A4 inhibitors. Pharmacologic response and disopyramide levels should be monitored more closely whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the disopyramide dosage adjusted as necessary.
- "Product Information. Norpace (disopyramide)." Searle, Skokie, IL.
Generic Name: disopyramide
Brand name: Norpace, Norpace CR
Synonyms: Disopyramide
Generic Name: dasabuvir / ombitasvir / paritaprevir / ritonavir
Brand name: Viekira XR, Viekira Pak
Synonyms: Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Disopyramide Sustained-Release Capsules-Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Tablets
- Disopyramide Sustained-Release Capsules-Omeclamox-Pak
- Disopyramide Sustained-Release Capsules-Omega-3 Fatty Acid Capsules
- Disopyramide Sustained-Release Capsules-Omega-3 Fatty Acids
- Disopyramide Sustained-Release Capsules-Omega-3 polyunsaturated fatty acids
- Disopyramide Sustained-Release Capsules-Omega-3-acid ethyl esters
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets-DisperMox
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets-Disposable Enema rectal
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets-Disulfiram
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets-Dithol Solution
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets-Ditropan
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets-Ditropan XL